|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, in this small case series we showed that MYD88 L265P mutation analysis could serve as a useful adjunct in distinguishing benign from lymphomatous PE in patients with LPL.
|
31556196 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The diagnosis of Waldenström Macroglobulinaemia (WM)/lymphoplasmacytic lymphoma (LPL) remains one of exclusion because other B-cell lymphoproliferative disorders (B-LPD), such as marginal zone lymphoma (MZL), can fulfil similar criteria, including MYD88 L265P mutation.
|
30198568 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The diagnosis of WM is established by the presence of lymphoplasmacytic lymphoma in the bone marrow or other organs, a monoclonal IgM paraproteinemia and the recurrent MYD88 L265P somatic mutation.
|
31591468 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.
|
31221512 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The mutation profile of MYD88 genes was evaluated by Sanger sequencing in a cohort of 97 patients [DLBCL (N=55), non-DLBCL lymphomas (N=30), reactive lymphadenopathy (N=10), and 2 cases of lymphoplasmacytic lymphoma (positive control)].
|
29734251 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<i>Results</i>: MYD88 L265P mutations were detected in 22 of 29 samples from 14 patients with diffuse large B-cell lymphomas and one patient with lymphoplasmacytoid lymphoma.
|
31603365 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
|
31483817 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MYD88 mutation has been reported in various lymphomas, specifically in lymphoplasmacytic lymphoma.
|
31576141 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
|
30183082 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
|
31276195 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The simultaneous presentation of Waldenström's macroglobulinemia and MYD88 mutation with multiple myeloma in the same patient is very rare and only a few cases have been reported in the literature.
|
30868035 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
MyD88-loaded EVs were detected in the bone marrow aspirates of WM patients thus establishing the physiological role of EVs for MyD88<sup>L265P</sup> transmission and shaping of the proinflammatory microenvironment.
|
29358175 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The MYD88 L265P mutation is present in nearly 90% of patients with Waldenström macroglobulinemia.
|
30190015 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
|
30401751 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Nine of these samples tested positive for MYD88 p.(L265P) (8 LPL and 1 PCNSL).
|
29210102 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Owing to low prevalence of the wild-type (WT) MYD88 genotype in WM, clinically relevant data in this patient population are sparse, with one study showing nearly a 10-fold increased risk of mortality in this subgroup compared to patients with MYD88<sup>L265P</sup> mutation.
|
29080258 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations in the MYD88 gene have been described in the majority of WM cases.
|
29637541 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Few cancers such as WM have a single amino acid substitution in one gene like MYD88 L265P that occurs in ∼90% of cases, making WM paradigmatic for study of a single causative mutation in oncogenesis.
|
29703722 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Diagnostic discrimination can be difficult among suspected wild-type MYD88 (MYD88<sup>WT</sup> ) WM cases.
|
29181840 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
To clarify if cytokine release by ibrutinib-treated BTK<sup>Cys481Ser</sup> cells could protect BTK<sup>WT</sup> MYD88-mutated malignant cells, we used a Transwell coculture system and showed that nontransduced BTK<sup>WT</sup> MYD88-mutated WM or ABC DLBCL cells were rescued from ibrutinib-induced killing when cocultured with BTK<sup>Cys481Ser</sup> but not their BTK<sup>WT</sup>-expressing counterparts.
|
29496671 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Review of our genetic data on diffuse large B cell lymphoma (DLBCL) and Waldenstrom macroglobulinemia (WM), found that a large percentage of DLBCL and WM cases that have a MYD88 mutation also harbor a TNFAIP3 loss, 55% DLBCL and 28% of WM, respectively.
|
30301877 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
CTD_human |
Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.
|
30126942 |
2018 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.
|
27840426 |
2017 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<b>Purpose:</b> Everolimus inhibits mTOR, a component of PI3K/AKT prosurvival signaling triggered by MYD88 and CXCR4-activating mutations in Waldenstrom macroglobulinemia.<b>Experimental design:</b> We evaluated everolimus in a prospective, multicenter study of 33 symptomatic, previously untreated Waldenstrom macroglobulinemia patients.
|
27836860 |
2017 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We identified the MYD88 L265P somatic variant in cases with WM (39/42), MGUS (8/18), NHL (14/41, including 4/13 diffuse large B cell lymphoma (DLBCL), 1/8 mucosa-associated lymphoid tissue, 3/6 splenic marginal zone lymphoma (SMZL), 1/4 chronic lymphocytic leukemia, 2/3 nodal marginal zone lymphoma (NMZL), 1/2 mantle cell lymphoma, 1 Burkitt lymphoma, and 1 B cell NHL that could not be classified), primary AL (2/2), and IgM-PN (1/1).
|
28280994 |
2017 |